Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
diacerein + glucosamine sulfate
- Development stage
- Phase 4
- Lead developer
- Navana Pharmaceuticals
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Bonacerin is an oral fixed-dose combination of diacerein and glucosamine sulfate, developed by Navana Pharmaceuticals for the symptomatic management of osteoarthritis, rheumatoid arthritis, and joint injuries. Diacerein is an anthraquinone derivative that acts as an anti-inflammatory agent by inhibiting the synthesis and activity of interleukin-1 (IL-1), a key cytokine involved in cartilage destruction and joint inflammation. Glucosamine sulfate is an amino sugar that serves as a fundamental building block for the biosynthesis of glycosaminoglycans and proteoglycans, which are essential components of articular cartilage. Together, these two agents provide complementary actions to relieve joint pain, reduce stiffness, and support cartilage repair and maintenance in degenerative joint diseases.
- Brand names
- Bonacerin
- Other names
- diacerein + glucosaminediacerein + glucosamine sulphateglucosamine + diacereinglucosamine sulfate + diacereinglucosamine sulphate + diacerein
02
Targets
SLC2A2 (Solute carrier family 2 facilitated glucose transporter member 2)IL1R1 (Interleukin-1 Receptor Type 1)IL1B (Interleukin-1 beta)CASP1 (Caspase-1)
Beyond the preview
Go deeper on diacerein + glucosamine sulfate.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on diacerein + glucosamine sulfate.